Brucella canis slyX antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Brucella canis slyX antibodies pairs and antigen for animal health (animal Cat/Feline infectious disease Canine brucellosis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Companion Animal disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P027-Tg001-Ag01	Recombinant Brucella canis slyX protein	$3090.00
GMP-VT-P027-Tg001-Ab01	Anti-Brucella canis slyX mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P027-Tg001-Ab02	Anti-Brucella canis slyX mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P027-Tg001-Ab03	Anti-Brucella canis slyX human monoclonal antibody (mAb)	$3090.00
GMP-VT-P027-Tg001-Ab04	Anti-Brucella canis slyX human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P027-Tg001-Ag01
Product Name	Recombinant Brucella canis slyX protein
Pathogen	Brucella canis
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Brucella canis slyX antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Brucella canis level test of animal Cat/Feline infectious disease with Canine brucellosis.
Tag	His
Product description	Recombinant Brucella canis slyX proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P027-Tg001-Ab01,GMP-VT-P027-Tg001-Ab02
Pathogen	Brucella canis
Product Name	Anti-Brucella canis slyX mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Brucella canis slyX antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Brucella canis antibodies in Brucella canis level test of animal Cat/Feline infectious disease with Canine brucellosis.
Product description	Anti-Brucella canis slyX mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Brucella canis antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P027-Tg001-Ab03,GMP-VT-P027-Tg001-Ab04
Pathogen	Brucella canis
Product Name	Anti-Brucella canis slyX human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Brucella canis slyX antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Brucella canis antibodies in Brucella canis level test of animal Cat/Feline infectious disease with Canine brucellosis.
Product description	Anti-Brucella canis slyX mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Brucella canis is a Gram-negative bacterium that primarily affects canines, causing Canine Brucellosis. It is considered a zoonotic pathogen, meaning it has the potential to be transmitted from animals to humans. In dogs, Brucella canis primarily infects the reproductive system, leading to various reproductive disorders, including infertility. Additionally, it can cause inflammation in lymph nodes, testicles, and other organs.

Brucella canis belongs to the genus Brucella, which comprises several other pathogens responsible for causing brucellosis in different animal species. The bacterium possesses a complex cell envelope structure, consisting of an outer membrane, periplasmic space, and inner membrane. The outer membrane contains lipopolysaccharides (LPS) on its surface, which play a significant role in its pathogenicity. The LPS is composed of O-antigens, core oligosaccharides, and lipid A.

The bacterium also possesses important virulence factors, including outer membrane proteins (Omps), such as Omp25 and Omp31. These proteins contribute to host cell invasion and immune evasion. The bacterium is adapted to survive intracellularly following uptake by phagocytic cells, where it can establish a chronic infection and evade the host's immune response.

Brucella canis primarily infects domestic dogs, leading to Canine Brucellosis. However, it can also affect other canids, such as coyotes and foxes. Brucellosis caused by other Brucella species can affect a wide range of animals, including cattle, goats, pigs, sheep, and even marine mammals.

In dogs, Canine Brucellosis results in reproductive problems, such as infertility, abortions, stillbirths, and the birth of weak or dead puppies. It can also cause inflammation of the lymph nodes, testicles, and other organs. The bacterium is shed in the reproductive fluids of infected animals, such as semen, vaginal discharge, and placental tissue, making it highly contagious.

Several diagnostic methods are available for detecting Brucella canis infection in dogs and other animals. These include serological tests, bacterial culture, and Polymerase Chain Reaction (PCR). Serological tests, such as agglutination tests, complement fixation tests, and enzyme-linked immunosorbent assays (ELISA), are commonly used to detect antibodies against Brucella canis in the blood serum of infected animals. These tests rely on the detection of specific antigens, including outer membrane proteins like Omp25 and Omp31.

Bacterial culture enables the isolation of Brucella canis from clinical samples, such as blood, urine, vaginal discharge, or aborted fetal tissues, using selective culture media. However, this approach requires specialized laboratory facilities and expertise. PCR-based methods enable the detection of Brucella canis DNA in clinical samples. Specific genes, such as bcsp31 and omp2a, are often targeted for amplification and subsequent identification of the pathogen.

Treatment of Canine Brucellosis is challenging, as the disease is often chronic and difficult to eliminate entirely. Antibiotics are the primary treatment, but they may not be entirely effective in eradicating the bacterium. Additionally, infected animals may need to undergo castration or spaying to prevent transmission of the disease.

Prevention of Brucella canis infection involves implementing strict biosecurity measures, such as screening of breeding animals, regular testing of animals, and isolation of infected animals. Vaccines are available in some countries but have limited efficacy, and their use may interfere with the diagnosis of infected animals.

In conclusion, Brucella canis is a significant pathogen that primarily affects canines, causing Canine Brucellosis. It is a zoonotic pathogen, and precautions must be taken to prevent transmission to humans. Various diagnostic methods are available for detecting the bacterium, but effective treatment and prevention strategies remain limited.

About GDU